# AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer

> **NCT04630756** · PHASE1,PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 40 (actual)

## Conditions studied

- Advanced Haematological Malignancies

## Interventions

- **DRUG:** AZD4573
- **DRUG:** Acalabrutinib

## Key facts

- **NCT ID:** NCT04630756
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-17
- **Primary completion:** 2023-09-08
- **Final completion:** 2025-02-27
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04630756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04630756, "AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT04630756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*